Together, these findings point out the importance of the PYK2/RSK2 signaling axis responsible for GPNMB-triggered GSC glycolysis and self-renewal and highlight the potential of testing PYK2 and RSK2 inhibitors in patients with GBM. This evidence concerns the gene RPS6KA3 and glioblastoma.